Why the study?
Does gemcitabine plus doxorubicin produce an acceptable response rate and safety profile in chemonaïve patients with advanced hepatocellular carcinoma?
Population
50 chemonaïve patients with advanced hepatocellular carcinoma, 47 men, 3 women, median age 53 years, Zubrod…
Design
Other
Follow-up
Median survival 4.6 months
Authors
Loading...
Modest phase II activity does not support clinical use in advanced HCC; leaves open randomized efficacy testing.
Does gemcitabine plus doxorubicin produce an acceptable response rate and safety profile in chemonaïve patients with advanced hepatocellular carcinoma?
Gemcitabine plus doxorubicin produces modest activity and moderate toxicity in Chinese patients with advanced hepatocellular carcinoma.
Yang et al. (2002) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: